UnitedHealthcare Community Plan

UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes

Meeting Date: March 6, 2025 Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/ Recommendations	Vote
leeting called to order		5:01PM EST		
Minutes from previous meetings		Review of Minutes from December 12, 2024	Minutes reviewed, approved	Yes
Formulary Review - New Drugs		Cobenfy		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Olanzapine ODT Recommendation: • Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Risperidone ODT	recommendation	
		Recommendation: • Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Paliperidone ER	Motion made,	
		Recommendation: Move to preferred across all applicable lines of business 	seconded, and carried to accept recommendation	9:0
		asked, if a member has had 100-pound weight gain; after trying several antipsychotics, but has not tried lurasidone, would this person be someone who would be approved for Cobenfy? replied each case would be reviewed on a case-by- case basis. The way the criteria is set up now it would be step through 3 preferred atypical antipsychotics, unless there is a extenuating circumstance for that patient specifically.		
		Ebglyss		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Adbry	Motion made,	
		Recommendation: Move to preferred with prior authorization across all applicable lines of business 	seconded, and carried to accept recommendation	9:0
		Aqneursa	Mation mode	
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Miplyffa		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Leqselvi		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	Comment:	asked is Leqselvi intended to be a lifetime medication. replied the trials were only up to 24 weeks. I think we're expecting long-term use since alopecia areata is a chronic condition, but as far as treatment for the lifetime of the patient that remains to be seen. Monitoring for safety would be important as with any other drug that's new to market, but there is nothing in the package insert about ending therapy after 24 weeks. Additionally, we do see other drugs in this class used long-term so Leqselvi would likely be the same. Qlosi		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Hympavzi Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0

	Itovebi Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	Revuforj Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	Vyalev Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	Dhivy Recommendation: • Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	Livdelzi Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	Yorvipath Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
Formulary Review - New Formulations	Confirm Review of New Formulations Grid Recommendation: • Erzofri: Non-preferred with prior authorization across all applicable lines of business	Yes/No Motion made, seconded, and carried to accept	Yes 10:0
	Recommendation: • Imkeldi: Non-preferred with prior authorization across all applicable lines of business	recommendation Motion made, seconded, and carried to accept recommendation	10:0
	Recommendation: • Opipza: Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation Motion made,	10:0
	Recommendation: • Zituvimet: Non-preferred with prior authorization across all applicable lines of business Recommendation:	seconded, and carried to accept recommendation Motion made,	10:0
	• Zituvimet XR: Non-preferred with prior authorization across all applicable lines of business	seconded, and carried to accept recommendation	10:0
Formulary Review - PDL Modifications	Confirm Review of PDL Modifications Grid Recommendation:	Yes/No Motion made, seconded, and carried	Yes
	Otulfi pre-filled syringe and vial: Preferred with prior authorization across all applicable lines of business	to accept recommendation Motion made,	10:0
	Recommendation: • Yesintek pre-filled syringe and vial: Preferred with prior authorization across all applicable lines of business Recommendation:	seconded, and carried to accept <u>recommendation</u> Motion made,	10:0
	Premarin tablet: Move to non-preferred with prior authorization across all applicable lines of business Recommendation: Prempro tablet: Move to non-preferred with prior	seconded, and carried to accept recommendation Motion made, seconded, and carried	10:0
	authorization across all applicable lines of business Recommendation: • Premphase tablet: Move to non-preferred with prior	to accept recommendation Motion made, seconded, and carried to accept	10:0
	authorization across all applicable lines of business Recommendation: •Duavee tablet: Move to non-preferred with prior authorization across all applicable lines of business	recommendation Motion made, seconded, and carried to accept	10:0
	Recommendation: • Norethindrone acetate/Ethinyl estradiol tablet: Move to preferred across all applicable lines of business	recommendation Motion made, seconded, and carried to accept recommendation	10:0
	Recommendation: • Estradiol/Norethindrone acetate tablet: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation Motion made,	10:0
	Recommendation: • Methadone (5mg and 10mg) tablet: Move to preferred with prior authorization across all applicable lines of business Recommendation:	seconded, and carried to accept recommendation Motion made,	10:0
	Oxymorphone ER tablet: Move to non-preferred with prior authorization across all applicable lines of business Recommendation:	seconded, and carried to accept recommendation Motion made, seconded, and carried	10:0
	Vandazole 0.75% vaginal gel: Move to non-preferred with prior authorization across all applicable lines of business	seconded, and carried to accept recommendation Motion made,	10:0
	Recommendation: • Epinephrine 0.3mg (Teva manufacturer) injection: Move to preferred across all applicable lines of business Recommendation:	seconded, and carried to accept <u>recommendation</u> Motion made,	10:0
	• Epinephrine 0.15mg (Teva manufacturer) injection: Move to preferred across all applicable lines of business	seconded, and carried to accept <u>recommendation</u> Motion made,	10:0
	Recommendation: • Sevelamer carbonate tablet: Move to preferred across all applicable lines of business Recommendation:	seconded, and carried to accept recommendation Motion made,	10:0
	Recommendation: • Soliqua: Move to preferred with Dx2Rx across all applicable lines of business Recommendation:	seconded, and carried to accept recommendation Motion made,	10:0
	• Sogroya injection: Move to preferred with prior authorization across all applicable lines of business Recommendation:	seconded, and carried to accept recommendation Motion made, seconded, and carried	10:0
	 Norditropin injection: Move to preferred with prior authorization across all applicable lines of business Recommendation: Unithroid tablet: Move to non-preferred with prior 	to accept recommendation Motion made, seconded, and carried	10:0
	authorization across all applicable lines of business Recommendation:	to accept recommendation Motion made,	10.0
	• Lamotrigine ER tablet: Move to preferred across all applicable lines of business Recommendation:	seconded, and carried to accept recommendation Motion made, seconded, and carried	10:0
	 Levetiracetam ER tablet: Move to preferred across all applicable lines of business Recommendation: Clobazam tablet and solution: Move to preferred across all 	to accept recommendation Motion made, seconded, and carried	10:0
	applicable lines of business Recommendation: • Lacosamide tablet: Move to preferred across all applicable	to accept recommendation Motion made, seconded, and carried	10:0
	lines of business Recommendation: • Benznidazole tablet: Move to preferred across all applicable lines of business	to accept recommendation Motion made, seconded, and carried to accept	10:0
	Recommendation:	recommendation Motion made, seconded, and carried	10.0
	 Zepbound injection: Move to non-preferred with prior authorization across all applicable lines of business 	to accept recommendation	10:0

. Formulary Review - New Drugs- Medical		Confirm Review of New Drugs- Medical Grid	Yes	No
		Niktimvo Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		DycloPro Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Vyloy		
		Recommendation: Medical benefit with prior authorization required across all applicable lines of business 	Motion made, seconded, and carried to accept recommendation	10:0
		Aucatzyl Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
F. Formulary Review - Drugs Evaluated Per Grid		Apply recommendations as outlined in grid	Motion made, seconded, and carried to accept recommendation	10:0
G. Clinical Guidelines		Clinical Guideline Review		
		Apply New Pharmacy Guidelines	Motion made, seconded, and carried to accept recommendation	10:0
		Continue to Apply Pharmacy Guidelines Requiring Modifications	Motion made, seconded, and carried to accept recommendation	10:0
		Remove Pharmacy Guidelines Requiring Archival	Motion made, seconded, and carried to accept recommendation	10:0
I. Quality Monitoring		Confirm Review of Quality Data DUR Review	Yes/No	Yes
	Comment:	asked if declining volume in enrollments is due to redeterminations? Is that because of higher or stricter guidelines for qualifying for Medicaid? What do you suspect is the reason? replied, the overall decrease in enrollment that we are seeing in Lock-in is due to the decrease in Medicaid membership here at UnitedHealthcare due to redeterminations. With Community and State added, during the COVID period there was a relaxation of rules to qualify for Medicaid. After COVID was over, and all the emergency provisions were removed, the conditions to qualify and stay on Medicaid were tightened. That was what we called redeterminations.		
		Drug Recalls – 4th Quarter 2024		
		Top 25 Drugs by Spend and Volume – 4th Quarter 2024 Top 10 Drugs Requested - Approvals and Denials – 4th Quarter	2024	
		Grievances and Appeals Data – 4th Quarter 2024 asked if the appeals data for Spravato is for Pennsylvania?		
	Comment:	replied, it is not for Pennsylvania. asked if the volume is for one market in particular for Spravato? replied, what we are seeing upon our initial review of the appeals data, is that it appears it is confined to one provider in one market. When looking at the information it seems most of the requests are being denied due to lack of information and then overturned once the information is received by the appeals team. We provided this information to our internal plan partner to look into this further.		
		Inter-Rater Reliability (IRR) – 4th Quarter 2024 • Pharmacists		
Adjournment		6:45PM EST		
Respectfully Submitted to the Committee,				